| Item type |
デフォルトアイテムタイプ_（フル）(1) |
| 公開日 |
2023-03-18 |
| タイトル |
|
|
タイトル |
Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan |
|
言語 |
en |
| 作成者 |
Kawai, Toru
Kusano, Yoshie
Yamada, Kyouko
Ueda, Chikako
Kawai, Atsushi
Masaki, Takao
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
権利情報 |
© The Japanese Society for Artificial Organs 2018. The final publication is available at www.springerlink.com. |
| 権利情報 |
|
|
権利情報 |
This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Continuous erythropoiesis receptor activator |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Epoetin beta pegol |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Hemoglobin |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Hemodialysis |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
Anemia |
| 内容記述 |
|
|
内容記述 |
Recent evidence on maintenance administration of epoetin beta pegol, a continuous erythropoiesis receptor activator (CERA), in dialysis patients shows the clinical benefit of bi-weekly administration (Q2W) in improving hematopoiesis and iron use efficiency. We undertook a single-center observational study of 33 Japanese maintenance dialysis patients, whose anemia had been kept stable through weekly administration (Q1W) of darbepoetin (DA), to evaluate the effectiveness of CERA Q2W switched from DA in maintaining hemoglobin (Hb) levels over a 12-month period. The target Hb level was 10.0–12.0 g/dL. Throughout the 12-month period, the mean Hb was stably maintained at 10.5–10.8 g/dL, 69.7–87.9% of the patients achieving the target Hb level. The mean CERA dose was within the range of 62.9–78.8 µg/2 weeks. The average CERA dose adjustment frequency after switching was low at 0.42–0.67 times/3 months. In both subgroups stratified by the DA dose prior to the switch, Hb levels were kept stable during CERA administration; however, in the low-dose group (10–20 µg/week of DA), the CERA and iron doses decreased over time, whereas in the high-dose group (30–60 µg/week of DA) they remained unchanged. CERA Q2W achieved long-term successful anemia management in Japanese maintenance dialysis patients after switching from DA Q1W. CERA dose was adjusted based on an overall consideration of past changes in Hb levels, erythropoiesis-stimulating agent and iron doses. Subgroup analysis showed the CERA dose in the low-dose group decreased continuously, due possibly to a long-term improvement in iron use efficiency. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Springer Japan |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
AO |
|
出版タイプResource |
http://purl.org/coar/version/c_b1a7d7d4d402bcce |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1007/s10047-018-1080-z |
| 関連情報 |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
30426250 |
| 関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1007/s10047-018-1080-z |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1434-7229 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1619-0904 |
| 開始ページ |
|
|
開始ページ |
146 |
| 書誌情報 |
Journal of Artificial Organs
Journal of Artificial Organs
巻 22,
号 2,
p. 146-153,
発行日 2018-11-14
|
| 旧ID |
47664 |
| 備考 |
Post-print version/PDF may be used in an institutional repository after an embargo period of 12 months. |
JArtifOrgans_22_146.pdf (549.5 KB)
